Core Insights - The 20th National Congress of the Communist Party of China has identified biomanufacturing as one of the six key future industries for the 14th Five-Year Plan, marking it as a significant direction for national strategic planning [1] - The implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of Biomedical New Technologies" in May 2026 will provide robust policy support for the industry [1] - Under the dual policy benefits, China's pharmaceutical industry is transitioning from "follow-up innovation" to "systematic innovation," with a focus on source innovation and the integration of AI and biotechnology [1] Industry Opportunities - Seer Medical is transitioning from a traditional medical supply chain service provider to a "technology-driven biomanufacturing platform," capitalizing on three key opportunities presented by the 14th Five-Year Plan: focus on cutting-edge fields like gene and cell therapy, the necessity of full-chain manufacturing capabilities, and the deep integration of AI and biotechnology [2][3] Technological Developments - Seer Medical is focusing on "AI intelligent diagnosis" and "innovative therapies," developing a diversified layout system, including an automatic intelligent microbial drug sensitivity testing instrument and an intelligent expert diagnostic system in collaboration with Fudan University [3] - The company is also advancing the TriVerity™ AI-assisted triage system for acute infections and sepsis, aiming to provide cutting-edge molecular diagnostic solutions [4] Innovations in Drug Development - The company’s subsidiary, Huajiyuan, is progressing with a new class I therapeutic hypertension vaccine, which has received clinical trial approval and is expected to revolutionize chronic disease management [5] - The "Haishi Lingxi" digital system for mental health has been implemented in clinical settings, focusing on brain disease digital treatment [6] Global Strategy - Seer Medical positions itself as a "dual-circulation value hub," leveraging global technology and local manufacturing to enhance resource and value circulation [7] - The company is actively introducing advanced biomanufacturing technologies and solutions to emerging markets, demonstrating the efficiency of "Chinese manufacturing" [8] Future Directions - The company aims to build an AI-enabled ecosystem in biomanufacturing, focusing on smart hospital management and therapeutic vaccines, aligning with the national development plan [9] - Seer Medical is committed to becoming a key player in the cell therapy industrialization infrastructure, emphasizing the integration of core equipment, compliant production, and clinical channels [10]

Core Viewpoint - The company has announced a temporary shareholders' meeting on January 7, 2026, to review the expansion of its business scope and amendments to its Articles of Association [1] Group 1: Business Scope Changes - The company has completed the business scope change and the filing procedures for the amended Articles of Association, obtaining a new business license [1] - The expanded business scope now includes the leasing of Class I medical devices, general equipment repair, and the leasing of Class III medical devices, as well as pharmaceutical wholesale [1] Group 2: Regulatory Compliance - The company has disclosed the full text of the amended Articles of Association on the Shanghai Stock Exchange website, confirming the completion of the registration process [1]

塞力斯医疗科技集团股份有限公司 章 程 2026 年 1 月 1 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | 第一节 | 股份发行 5 | | 第二节 | 股份增减和回购 6 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东会 8 | | 第一节 | 股东的一般规定 8 | | 第二节 | 控股股东和实际控制人 10 | | 第三节 | 股东会的一般规定 11 | | 第四节 | 股东会的召集 15 | | 第五节 | 股东会的提案与通知 16 | | 第六节 | 股东会的召开 17 | | 第七节 | 股东会的表决和决议 20 | | 第五章 | 董事和董事会 23 | | 第一节 | 董事的一般规定 23 | | 第二节 | 董事会 26 | | 第三节 | 独立董事 31 | | 第四节 | 董事会专门委员会 33 | | 第六章 | 高级管理人员 35 | | 第七章 | 财务会计制度、利润分配和审计 37 | | 第一节 | 财务会计制度 37 | | 第二节 | 内部审计 40 | | 第三节 ...

二、工商变更登记情况 公司于近日完成了经营范围的工商变更及《公司章程》的备案手续，并取得 了武汉市东西湖区行政审批局换发的《营业执照》。 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2026-005 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于 2026 年 1 月 7 日召开 2026 年第一次临时股东会，审议通过了《关于增加公司经营范围及相应 修订<公司章程>的议案》。具体内容详见公司于 2025 年 12 月 23 日在上海证券 交易所网站（www.sse.com.cn)披露的《关于增加公司经营范围及相应修订<公司 章程>的公告》（公告编号：2025-101）。 经营范围：一般项目：第一类医疗器械销售，第一类医疗设备租赁，第二类 医疗器械销售，第二类医疗设 ...

Group 1 - The stock of Saily Medical (603716) decreased by 0.96% today, with a turnover rate of 31.31% and a trading volume of 1.947 billion yuan, showing a fluctuation of 16.53% [2] - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its high turnover rate, with a net sell of 30.5364 million yuan from the Shanghai-Hong Kong Stock Connect [2] - Over the past six months, the stock has appeared on the Dragon and Tiger List 18 times, with an average price increase of 3.44% the day after being listed and an average increase of 11.40% in the following five days [2] Group 2 - The company's Q3 report for 2025 revealed a total revenue of 857 million yuan for the first three quarters, representing a year-on-year decline of 39.64%, and a net loss of 87.2441 million yuan [2] - The main capital outflow for the stock today was 60.3619 million yuan, with a significant outflow of 21.9535 million yuan from large orders and 38.4084 million yuan from major orders [2] - In the last five days, the stock has seen a total net outflow of 67.7795 million yuan [2]

Group 1 - The core point of the news is that Sely Medical has seen a significant stock price increase of 5.12% on January 13, reaching 30.58 CNY per share, with a total market capitalization of 6.428 billion CNY and a trading volume of 862 million CNY, indicating a 20.01% cumulative increase over three consecutive days [1] - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, is based in Wuhan, Hubei Province, and specializes in medical testing services, agency of in vitro diagnostic products, and the research, production, and sales of its own in vitro diagnostic products [1] - The company's main business revenue composition includes IVD business at 39.91%, SPD business at 38.01%, and pure sales at 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under GF Fund ranks among them, specifically the GF Healthcare Stock A (004851), which entered the top ten shareholders in the third quarter with 1.2236 million shares, accounting for 0.58% of circulating shares [2] - The GF Healthcare Stock A fund has a current scale of 5.185 billion CNY and has achieved a year-to-date return of 10.14%, ranking 1178 out of 5517 in its category, with a one-year return of 25.72%, ranking 3223 out of 4203 [2] - The fund manager, Wu Xingwu, has been in position for 10 years and 339 days, overseeing a total fund asset scale of 10.641 billion CNY, with the best fund return during his tenure being 102.67% and the worst being -38.11% [2]

截至2026年1月12日收盘，塞力医疗(603716)报收于29.09元，上涨4.53%，换手率32.78%，成交量68.9万 手，成交额19.36亿元。 当日关注点 交易信息汇总资金流向 1月12日主力资金净流出3448.45万元，占总成交额1.78%；游资资金净流入362.04万元，占总成交额 0.19%；散户资金净流入3086.41万元，占总成交额1.59%。 龙虎榜上榜 沪深交易所2026年1月12日公布的交易公开信息显示，塞力医疗（603716）因有价格涨跌幅限制的日换 手率达到20%的前五只证券登上龙虎榜。此次是近5个交易日内第4次上榜。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月12日塞力医疗主力资金净流出3448.45万元，占总成交额1.78%。 来自交易信息汇总：塞力医疗因日换手率达20%于1月12日登龙虎榜，近5个交易日内第4次上榜。 ...

塞力医疗1月12日交易公开信息 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即买三，合计净买入2536.87万元，沪股 通为第一大买入营业部及第一大卖出营业部，买入金额为2969.40万元，卖出金额为6928.18万元，合计 净卖出3958.78万元。 近半年该股累计上榜龙虎榜17次，上榜次日股价平均涨3.72%，上榜后5日平均涨12.38%。 资金流向方面，今日该股主力资金净流出5115.44万元，其中，特大单净流出2142.48万元，大单资金净 流出2972.95万元。近5日主力资金净流入6337.74万元。 2025年10月30日公司发布的三季报数据显示，前三季度公司共实现营业收入8.57亿元，同比下降 39.64%，实现净利润-8724.41万元。（数据宝） 塞力医疗(603716)今日上涨4.53%，全天换手率32.78%，成交额19.36亿元，振幅12.69%。龙虎榜数据显 示，机构净买入2536.87万元，沪股通净卖出3958.78万元，营业部席位合计净卖出1217.18万元。 上交所公开信息显示，当日该股因日换手率达32.78%上榜，机构专用席位净买入2536.87万元，沪股通 净 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Group 1 - The A-share market saw a strong performance in brain-computer interface concept stocks, with several companies approaching or hitting their daily limit up [1] - Notable gainers included Entropy Technology, which approached a 20% limit up, and Dao's Technology and Yingkang Life, both rising over 13% [1] - Other significant performers included Tom Cat, which increased by over 10%, and Yanshan Technology, which hit a 10% limit up [1] Group 2 - The table lists various companies with their respective stock codes, percentage increase, total market capitalization, and year-to-date performance [2] - Entropy Technology (301330) had a 19.40% increase, with a market cap of 11.7 billion and a year-to-date increase of 50.11% [2] - Dao's Technology (300409) rose by 13.91%, with a market cap of 25.9 billion and a year-to-date increase of 47.49% [2] - Yingkang Life (300143) increased by 13.01%, with a market cap of 10 billion and a year-to-date increase of 35.43% [2] - Other companies like Tom Cat (300459) and Yanshan Technology (002195) also showed significant gains, with year-to-date increases of 29.63% and 60.65% respectively [2]